Dr. John H. Krystal, world-leading expert in alcoholism and depression, will serve on scientific advisory board
VANCOUVER, June 21, 2022 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (CSE: CMND, OTC Pink: CMNDF, FSE: CWY0) (Clearmind or the "Company"), a biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major undertreated health problems, today announced the appointment to its Scientific Advisory Board of John Krystal, Chair of the Psychiatry Department at Yale Universitys School of Medicine.
A leading expert on alcoholism, post-traumatic stress disorder, schizophrenia, and depression, Dr. Krystals work links psychopharmacology, neuroimaging, molecular genetics, and computational neuroscience to study the neurobiology and treatment of these disorders. He is best known for leading the discovery of the rapid antidepressant effects of ketamine.
"We are truly honored to add Dr. Krystal, one of the worlds most recognized experts in alcoholism, to our Scientific Advisory Board, said Dr. Adi Zuloff-Shani, Clearmind's Chief Executive Officer. Clearmind has emphasized collaboration with scientists and clinicians at the very best academic, medical and research institutions in the world, helping us bring innovative expertise to bear on some of the most pressing global health needs.
Dr. Krystal is a Professor of Translational Research; Psychiatry, Neuroscience, and Psychology; he chairs the Department of Psychiatry at Yale University; and he is Chief of Psychiatry and Behavioral Health at Yale-New Haven Hospital. He is a graduate of the University of Chicago and the Yale University School of Medicine
Among many other positions he holds or has held, Dr. Krystal is the Director of the NIAAA Center for the Translational Neuroscience of Alcoholism and the Clinical Neuroscience Division of the VA National Center for PTSD, co-director of the Neuroscience Forum of the U.S. National Academies of Sciences, Engineering, and Medicine; and editor of Biological Psychiatry (IF=12.1). He is a member of the U.S. National Academy of Medicine and a Fellow of the American Association for the Advancement of Science.
We believe that the scientists on our Scientific Advisory Board, working closely with us to challenge, validate and guide our scientific agenda for developing breakthrough therapies that improve human mental-health at scale, increase access to care, reduce suffering and improve health outcomes around the world, said Zuloff-Shani.
About Clearmind Inc. (CSE: CMND), (OTC: CMNDF), (FSE:CWY0)
Clearmind is a new biotech company focused on the discovery and development of safe and novel psychedelic-derived therapeutics to treat alcohol use disorder and other pressing health challenges.
The Israeli Canadian company holds several patents for the non-hallucinogenic compound MEAI (5-methoxy-2-aminoindane, a novel psychoactive substance). The company intends to seek additional patents for its compounds whenever warranted and will remain opportunistic regarding the acquisition of additional intellectual property to build its portfolio.
Clearmind has established a research collaboration with the Hebrew University of Jerusalem and Bar Ilan University. The partnerships aim to expand its R&D capabilities and discover new candidate treatments for other mental health issues.
For further information, please contact:
Investor Relations
Telephone: (604) 260-1566
General Inquiries
http://www.Clearmindmedicine.com
FORWARD-LOOKING STATEMENTS:
This news release may contain forward-looking statements and information based on current expectations. These statements should not be read as guarantees of future performance or results. Such statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by such statements. Such statements include submission of the relevant documentation within the required timeframe to the satisfaction of the relevant regulators and raising sufficient financing to complete the Company's business strategy. There is no certainty that any of these events will occur. Although such statements are based on management's reasonable assumptions, there can be no assurance that such assumptions will prove to be correct. We assume no responsibility to update or revise them to reflect new events or circumstances.
Investing into early-stage companies inherently carries a high degree of risk, and investment into securities of the Company shall be considered highly speculative.
This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of the securities in any province in which such offer, solicitation or sale would be unlawful. The securities issued, or to be issued, under the Private Placement have not been, and will not be, registered under the United States Securities Act of 1933, as amended, and may not be offered or sold in the United States absent registration or an applicable exemption from registration requirements.
Neither the Canadian Securities Exchange (the CSE) nor its Regulation Services Provider (as that term is defined in the policies of the CSE) accepts responsibility for the adequacy or accuracy of this release.
Visit link:
Yale's Department of Psychiatry Chair to Join Clearmind Medicine - The Bakersfield Californian
- 8: Techniques of Molecular Genetics - Biology LibreTexts - January 23rd, 2024
- Molecular Genetics and Metabolism Reports - ScienceDirect - December 18th, 2022
- Molecular Genetics and Metabolism | Journal - ScienceDirect - December 18th, 2022
- Molecular clock - Wikipedia - December 2nd, 2022
- Molecular Structure of Nucleic Acids: A Structure for Deoxyribose ... - December 2nd, 2022
- Molecular Genetics School of Graduate Studies - University of Toronto - October 13th, 2022
- Molecular pathways of major depressive disorder converge on the synapse | Molecular Psychiatry - Nature.com - October 13th, 2022
- Can artificial intelligence help identify best treatments for cancers? LSU researchers say yes - The Advocate - October 13th, 2022
- Results for the fiscal year on June 30, 2022 - Yahoo Finance - October 13th, 2022
- From the journals: MCP - ASBMB Today - October 13th, 2022
- From cave-dweller scientist to Nobel laureate - The Tribune India - October 13th, 2022
- Animal Genetics Market - Know the Revenue and Profit-Sources of the Industry - openPR - October 13th, 2022
- Molecular and Cell Biology and Genetics - Master of Science / PhD ... - September 25th, 2022
- What does the future hold for COVID-19? - UCLA Health Connect - September 25th, 2022
- Farooq Kperogi: Lies and truth about Obi, Atiku, and Tinubu - Peoples Gazette - September 25th, 2022
- Atavistik Bio Announces Formation of Scientific Advisory Board - Business Wire - September 25th, 2022
- Scientific Advances Point to Improved Understanding of Radiation Exposure - Livermore Independent - September 25th, 2022
- 19 million to investigate bold ideas in bioscience research - EurekAlert - September 25th, 2022
- Machel, Iwer among full list of National Awardees - Trinidad Guardian - September 25th, 2022
- Newly Discovered Protein Connected to Alzheimers Disease Risk - Neuroscience News - September 25th, 2022
- The Lab Report: Sharma Lab studies biodiversity of arachnids - The Badger Herald - September 16th, 2022
- Environmental Scientist Jesse Ausubel to Receive 2022 Nierenberg Prize for Science in the Public Interest - Scripps Institution of Oceanography - September 16th, 2022
- Malaria vax promising, to be cheap too - The Hans India - September 16th, 2022
- Dayton Therapeutics Discovers New Therapeutic Uses of Satraplatin for Treatment of Rare Lymphomas - StreetInsider.com - September 16th, 2022
- JNCASRs novel molecule prevents obesity in mice - The Hindu - September 16th, 2022
- Research Fellow in the Department of Medical and Molecular Genetics job with KINGS COLLEGE LONDON | 308234 - Times Higher Education - September 8th, 2022
- Seven Queen's researchers elected to the Royal Society of Canada - Queen's University - September 8th, 2022
- Molecular Biology with an Industrial Placement Year BSc - India Education Diary - September 8th, 2022
- Whole Exome Sequencing Market Projected to Reach CAGR of 19.0% Forecast by 2029, Global Trends, Size, Share, Growth, Future Scope and Key Player... - September 8th, 2022
- Molecular prevalence and genetic diversity of Bartonella spp. in stray cats of zmir, Turkey - Parasites & Vectors - Parasites & Vectors - August 30th, 2022
- How light and temperature work together to affect plant growth - EurekAlert - August 30th, 2022
- Ancient Mummies' Lousy View of the Past - The Scientist - August 30th, 2022
- 'Gray blanket' over Australia: Genetics may have aided European rabbit invasion of continent in 1859, says study - Down To Earth Magazine - August 30th, 2022
- Meet the UNC Pembroke professor leading research on Alzheimers disease - The Robesonian - August 30th, 2022
- Massive Genome Study Informs the Biology of Reading and Language - Neuroscience News - August 30th, 2022
- People in the News at Gencove, IsoPlexis, HTG Molecular, More - GenomeWeb - August 30th, 2022
- Professor (with Head of Department potential), Department of Medical & Molecular Genetics job with KINGS COLLEGE LONDON | 304203 - Times Higher... - August 14th, 2022
- Kathy C. Cordes, a former Baltimore Sun artist who later worked at NASA's Space Telescope Institute, dies Baltimore Sun - Baltimore Sun - August 14th, 2022
- Discovery of the interactions between plants and arbuscular mycorrhizal fungi - EurekAlert - August 14th, 2022
- A new drug could repair stroke damage to memory and movement - Freethink - August 14th, 2022
- CDC Says Recent Flu Season Mild, Maybe Owing to COVID Precautions - Medscape - August 14th, 2022
- Study Using NanoStrings GeoMx Digital Spatial Profiler Featured on the Cover of Nature Genetics - BioSpace - August 14th, 2022
- New virus detected in China; here's everything you need to know about it - WCCO - August 14th, 2022
- Relief Therapeutics and Acer Therapeutics Announce that the European Commission Has Granted Orphan Drug Designation for ACER-001 in Maple Syrup Urine... - August 14th, 2022
- Psychiatry, Fraud, and the Case for a Class-Action Lawsuit - Mad In America - Mad in America - August 14th, 2022
- Scientists Grow Mouse Embryos Without Sperm Or Eggs - EverythingGP - August 14th, 2022
- The Pitfalls of Evolutionary Genomics - SciTechDaily - August 14th, 2022
- How a simple home DNA test unravelled the genetic code that could help prolong my life - The National - August 14th, 2022
- Graduate Research Officer job with UNIVERSITY OF WESTERN AUSTRALIA | 304277 - Times Higher Education - August 14th, 2022
- These Are the Degrees of the Future - Gizmodo - August 14th, 2022
- University of Chicago obituaries - University of Chicago - August 14th, 2022
- Letter: Abortion and social planning - Daily Herald - August 14th, 2022
- Postdoctoral Researcher, Seaweed Molecular Biology, Physiology and Genetics, Ryan Institute, School job with NATIONAL UNIVERSITY OF IRELAND, GALWAY |... - August 5th, 2022
- Researchers crack 30-year-old mystery of odour switching in worms - University of Toronto - August 5th, 2022
- 1st synthetic mouse embryos complete with beating hearts and brains created with no sperm, eggs or womb - Livescience.com - August 5th, 2022
- Rallybio Appoints Wendy K. Chung, M.D., Ph.D., to Its Board of Directors - Business Wire - August 5th, 2022
- Luke Goldman: Using eDNA to save the Atlantic cod - UMaine News - University of Maine - University of Maine - August 5th, 2022
- Duke Announces Winners of the 2022 DST Spark Seed Grants - Duke Today - July 27th, 2022
- WVXU: UC scientists are deep-freezing molecules. Here's why they're so excited about it - University of Cincinnati - July 27th, 2022
- Better Diagnosis and Treatment: Genetic Clues to Age-Related Macular Degeneration - SciTechDaily - July 27th, 2022
- Regeneron Announces the 2022 Winners of the Regeneron Prize for Creative Innovation - PR Newswire - July 27th, 2022
- Replay Launches with $55 Million Seed to Reprogram Biology by Writing and Delivering Big DNA - GlobeNewswire - July 27th, 2022
- How is Biotechnology revolutionising food and beverage industry? - The Statesman - July 27th, 2022
- ACP offers guidance on the ethical use of genetic testing and precision medicine - EurekAlert - July 27th, 2022
- Barbour Appointed Dean of The Graduate School and Vice Provost for Graduate Education - Duke Today - July 19th, 2022
- UC scientists are deep-freezing molecules. Here's why they're so excited about it - WVXU - July 19th, 2022
- Research Fellow, Molecular Biology / Recombinant Protein Production and Purification (Biol Sci) job with NATIONAL UNIVERSITY OF SINGAPORE | 301436 -... - July 19th, 2022
- UF researchers discover new way to inhibit virus that causes COVID-19 - University of Florida - July 19th, 2022
- Streamlined Genomic Testing Platforms Are Taking on A Bigger Role in Cancer Care - OncLive - July 19th, 2022
- Bachelor of Science in Biology - National University - July 19th, 2022
- Genes may influence our successes and failures in life, according to Professor Kathryn Paige Harden - ABC News - July 19th, 2022
- Lecturer for Department of Experimental Biology job with MASARYK UNIVERSITY | 301048 - Times Higher Education - July 19th, 2022
- Lecturer in Biology (Education Focused) job with UNIVERSITY OF SYDNEY | 300815 - Times Higher Education - July 19th, 2022
- People's University Is All About Dinosaurs This Summer - Wheeling Intelligencer - July 19th, 2022
- Radiologists hope to use AI to improve readings - University of Miami: News@theU - July 19th, 2022
- Rare Disease Genetic Testing Market 2022 Emerging Trends, Comprehensive Study With Top Companies and Key Players till 2030 - Taiwan News - July 11th, 2022
- Proteases implicated in ulcerative colitis - ASBMB Today - July 11th, 2022
- Cancer has been a scourge for centuries, advances in science have made the disease far less intractable - The Indian Express - July 11th, 2022
- Scientists discover key genes behind insect migrations - EurekAlert - July 11th, 2022
- Neuroimaging Techniques and What a Brain Image Can Tell Us - Technology Networks - July 11th, 2022